Scholarly Review
Vascular tumours in infants. Part II: vascular tumours of intermediate dignity and malignant tumours
Correction(s) for this article
-
Corrigenda
- Volume 172Issue 1British Journal of Dermatology
- pages: 307-307
- First Published online: January 11, 2015
I. Colmenero,
P.H. Hoeger,
I. Colmenero
Histopathology Department, Birmingham Children's Hospital, Birmingham, U.K
Search for more papers by this authorCorresponding Author
P.H. Hoeger
Paediatric Dermatology Department, Catholic Children's Hospital Wilhelmstift, Hamburg, Germany
Correspondence
Peter Hoeger.
E-mail:[email protected]
Search for more papers by this authorI. Colmenero,
P.H. Hoeger,
I. Colmenero
Histopathology Department, Birmingham Children's Hospital, Birmingham, U.K
Search for more papers by this authorCorresponding Author
P.H. Hoeger
Paediatric Dermatology Department, Catholic Children's Hospital Wilhelmstift, Hamburg, Germany
Correspondence
Peter Hoeger.
E-mail:[email protected]
Search for more papers by this authorFunding sources None.
Conflicts of interest None declared.
Summary
Malignant cutaneous vascular tumours are very uncommon in children. As in adults, they are aggressive neoplasms with metastatic potential and a high mortality rate. Some nonmalignant vascular tumours may exhibit a locally aggressive behaviour and some of them can be associated with life-threatening systemic complications such as Kasabach–Merritt syndrome. Early diagnosis of these aggressive neoplasms in children is very important in order to start appropriate therapy as soon as possible, as this can have a significant impact on the prognosis of these patients. This review focuses on cutaneous vascular tumours of intermediate dignity (tufted angioma, kaposiform haemangioendothelioma, multifocal lymphangioendotheliomatosis with thrombocytopenia, papillary intralymphatic angioendothelioma, retiform haemangioendothelioma, adult-type haemangioendotheliomas) and malignant vascular tumours in young children (Kaposi sarcoma, angiosarcoma).
References
- 1Enjolras O, Wassef M, Mazoyer E et al. Infants with Kasabach-Merritt syndrome do not have ‘true’ hemangiomas. J Pediatr 1997; 130: 631–40.
- 2Lyons LL, North PE, Mac-Moune Lai F et al. Kaposiform hemangioendothelioma: a study of 33 cases emphasizing its pathologic, immunophenotypic, and biologic uniqueness from juvenile hemangioma. Am J Surg Pathol 2004; 28: 559–68.
- 3Le Huu AR, Jokinen CH, Rubin BP et al. Expression of PROX1, lymphatic endothelial nuclear transcription factor, in Kaposiform hemangioendothelioma and tufted angioma. Am J Surg Pathol 2010; 34: 1563–73.
- 4Arai E, Kuramochi A, Tsuchida T et al. Usefulness of D2-40 immunohistochemistry for differentiation between kaposiform hemangioendothelioma and tufted angioma. J Cutan Pathol 2006; 33: 492–7.
- 5Cohen MM. Vascular update: morphogenesis, tumors, malformations, and molecular dimensions. Am J Med Genet 2006; 140: 2013–38.
- 6Astarita JL, Acton SE, Turley SJ. Podoplanin: emerging functions in development, the immune system, and cancer. Front Immunol 2012; 3: 283.
- 7Navarro-Núñez L, Langan SA, Nash GB, Watson SP. The physiological and pathophysiological roles of platelet CLEC-2. Thromb Haemost 2013; 109: 991–8.
- 8Ozaki Y, Suzuki-Inoue K, Inoue O. Novel interactions in platelet biology: CLEC-2/podoplanin and laminin/GPVI. J Thromb Haemost 2009; 7(Suppl. 1): 191–4.
- 9Bertozzi CC, Schmaier AA, Mericko P et al. Platelets regulate lymphatic vascular development through CLEC-2–SLP-76 signaling. Blood 2010; 116: 661–70.
- 10Lowe KL, Navarro-Nunez L, Watson SP. Platelet CLEC-2 and podoplanin in cancer metastasis. Thromb Res 2012; 129(Suppl. 1): S30–7.
- 11Suzuki-Inoue K. Essential in vivo roles of the platelet activation receptor CLEC-2 in tumour metastasis, lymphangiogenesis and thrombus formation. J Biochem 2010; 150: 127–32.
- 12Ogasawara S, Kaneko MK, Price JE, Kato Y. Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2. Hybridoma (Larchmt) 2008; 27: 259–67.
- 13Suzuki-Inoue K, Inoue O, Ozaki Y. Novel platelet activation receptor CLEC-2: from discovery to prospects. J Thromb Haemost 2011; 9(Suppl. 1): 44–55.
- 14Kato Y, Kaneko MK, Kunita A et al. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci 2008; 99: 54–61.
- 15Suzuki-Inoue K, Inoue O, Ding G et al. Essential in vivo roles of the C-type lectin receptor CLEC-2: embryonic/neonatal lethality of CLEC-2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets. J Biol Chem 2010; 285: 24494–507.
- 16Wilson-Jones E, Orkin M. Tufted angioma (angioblastoma). A benign progressive angioma, not to be confused with Kaposi's sarcoma or low-grade angiosarcoma. J Am Acad Dermatol 1989; 20: 214–25.
- 17Nakagawa K. Case report of angioblastoma of the skin. Nihon Hifuka Gakkai Zasshi 1949; 59: 92–4.
- 18Macmillan A, Champion RH. Progressive capillary haemangioma. Br J Dermatol 1971; 85: 492–3.
- 19Heagerty AH, Rubin A, Robinson TW. Familial tufted angioma. Clin Exp Dermatol 1992; 17: 344–5.
- 20Hebeda CL, Scheffer E, Starink TM. Tufted angioma of late onset. Histopathology 1993; 23: 191–3.
- 21Fukunaga M. Intravenous tufted angioma. APMIS 2000; 108: 287–92.
- 22Kleinegger CL, Hammond HL, Vincent SD, Finkelstein MW. Acquired tufted angioma: a unique vascular lesion not previously reported in the oral mucosa. Br J Dermatol 2000; 142: 794–9.
- 23Maronn M, Chamlin S, Metry D. Multifocal tufted angiomas in 2 infants. Arch Dermatol 2009; 145: 847–8.
- 24Ishikawa K, Hatano Y, Ichikawa H et al. The spontaneous regression of tufted angioma. A case of regression after two recurrences and a review of 27 cases reported in the literature. Dermatology 2005; 210: 346–8.
- 25Suarez SM, Pensler JM, Paller AS. Response of deep tufted angioma to interferon alfa. J Am Acad Dermatol 1995; 33: 124–6.
- 26Herron MD, Coffin CM, Vanderhooft SL. Tufted angiomas: variability of the clinical morphology. Pediatr Dermatol 2002; 19: 394–401.
- 27Osio A, Fraitag S, Hadj-Rabia S et al. Clinical spectrum of tufted angiomas in childhood: a report of 13 cases and a review of the literature. Arch Dermatol 2010; 146: 758–63.
- 28Sadeghpour M, Antaya RJ, Lazova R, Ko CJ. Dilated lymphatic vessels in tufted angioma: a potential source of diagnostic confusion. Am J Dermatopathol 2012; 34: 400–3.
- 29Ban M, Kamiya H, Kitajima Y. Tufted angioma of adult onset, revealing abundant eccrine glands and central regression. Dermatology 2000; 201: 68–70.
- 30Trindade F, Tellechea O, Torrelo A et al. Wilms tumor 1 expression in vascular neoplasms and vascular malformations. Am J Dermatopathol 2011; 33: 569–72.
- 31North PE, Waner M, Mizeracki A, Mihm MC. GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol 2000; 31: 11–22.
- 32Hall GW. Kasabach-Merritt syndrome: pathogenesis and management. Br J Haematol 2001; 112: 851–62.
- 33Chiu YE, Drolet BA, Blei F et al. Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. Pediatr Blood Cancer 2012; 59: 934–8.
- 34Zukerberg LR, Nickoloff BJ, Weiss SW. Kaposiform hemangioendothelioma of infancy and childhood. An aggressive neoplasm associated with Kasabach-Merritt syndrome and lymphangiomatosis. Am J Surg Pathol 1993; 17: 321–8.
- 35North PE, Waner M, Buckmiller L et al. Vascular tumors of infancy and childhood: beyond capillary hemangioma. Cardiovasc Pathol 2006; 15: 303–17.
- 36Sarkar M, Mulliken JB, Kozakewich HP et al. Thrombocytopenic coagulopathy (Kasabach–Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg 1997; 100: 1377–86.
- 37Enjolras O, Mulliken JB, Wassef M et al. Residual lesions after Kasabach-Merritt phenomenon in 41 patients. J Am Acad Dermatol 2000; 42: 225–35.
- 38Walsh MA, Carcao M, Pope E, Lee KJ. Kaposiform hemangioendothelioma presenting antenatally with a pericardial effusion. J Pediatr Hematol Oncol 2008; 30: 761–3.
- 39Croteau SE, Liang MG, Kozakewich HP et al. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals. J Pediatr 2013; 162: 142–7.
- 40Debelenko LV, Perez-Atayde AR, Mulliken JB et al. D2-40 immunohistochemical analysis of pediatric vascular tumors reveals positivity in kaposiform hemangioendothelioma. Mod Pathol 2005; 18: 1454–60.
- 41Beaubien ER, Ball NJ, Storwick GS. Kaposiform hemangioendothelioma: a locally aggressive vascular tumor. J Am Acad Dermatol 1998; 38: 799–802.
- 42Adams DM, Wentzel MS. The role of the hematologist/oncologist in the care of patients with vascular anomalies. Pediatr Clin North Am 2008; 55: 339–55.
- 43Blatt J, Stavas J, Moats-Staats B et al. Treatment of childhood kaposiform hemangioendothelioma with sirolimus. Pediatr Blood Cancer 2010; 55: 1396–8.
- 44North PE, Kahn T, Cordisco MR et al. Multifocal lymphangioendotheliomatosis with thrombocytopenia: a newly recognized clinicopathological entity. Arch Dermatol 2004; 140: 599–606.
- 45Maronn M, Catrine K, North P et al. Expanding the phenotype of multifocal lymphangioendotheliomatosis with thrombocytopenia. Pediatr Blood Cancer 2009; 52: 531–4.
- 46Glick ZR, Frieden IJ, Garzon MC et al. Diffuse neonatal hemangiomatosis: an evidence-based review of case reports in the literature. J Am Acad Dermatol 2012; 67: 898–903.
- 47Esparza EM, Deutsch G, Stanescu L et al. Multifocal lymphangioendotheliomatosis with thrombocytopenia: phenotypic variant and course with propranolol, corticosteroids, and aminocaproic acid. J Am Acad Dermatol 2012; 67: e62–4.
- 48Noel RJ, Duffy KJ, Kelly ME et al. Endoscopic management of gastrointestinal bleeding from multifocal lymphangioendotheliomatosis with thrombocytopenia: limited efficacy and complications. J Pediatr Gastroenterol Nutr 2012; 54: 822–4.
- 49Dabska M. Malignant endovascular papillary angioendothelioma of the skin in childhood. Clinicopathologic study of 6 cases. Cancer 1969; 24: 503–10.
10.1002/1097-0142(196909)24:3<503::AID-CNCR2820240311>3.0.CO;2-L CAS PubMed Web of Science® Google Scholar
- 50Fanburg-Smith JC, Michal M, Partanen TA et al. Papillary intralymphatic angioendothelioma (PILA): a report of twelve cases of a distinctive vascular tumor with phenotypic features of lymphatic vessels. Am J Surg Pathol 1999; 23: 1004–10.
- 51Fletcher C, Unni K, Mertens F, eds. Vascular tumours. In: Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press, 2002; 155–78.
- 52Neves RI, Stevenson J, Hancey MJ et al. Endovascular papillary angioendothelioma (Dabska tumor): underrecognized malignant tumor in childhood. J Pediatr Surg 2011; 46: 25–8.
- 53McCarthy EF, Lietman S, Argani P, Frassica FJ. Endovascular papillary angioendothelioma (Dabska tumor) of bone. Skeletal Radiol 1999; 28: 100–3.
- 54Rodgers B, Zeim S, Crawford B et al. Splenic papillary angioendothelioma in a 6-year-old girl. J Pediatr Hematol Oncol 2007; 29: 808–10.
- 55Emanuel PO, Lin R, Silver L et al. Dabska tumor arising in lymphangioma circumscriptum. J Cutan Pathol 2008; 35: 65–9.
- 56Argani P, Athanasian E. Malignant endovascular papillary angioendothelioma (Dabska tumor) arising within a deep intramuscular hemangioma. Arch Pathol Lab Med 1997; 121: 992–5.
- 57Quecedo E, Martínez-Escribano JA, Febrer I et al. Dabska tumor developing within a preexisting vascular malformation. Am J Dermatopathol 1996; 18: 302–7.
- 58Calonje E, Fletcher CD, Wilson-Jones E, Rosai J. Retiform hemangioendothelioma. A distinctive form of low-grade angiosarcoma delineated in a series of 15 cases. Am J Surg Pathol 1994; 18: 115–25.
- 59Errani C, Zhang L, Sung YS et al. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosom Cancer 2011; 50: 644–53.
- 60Billings SD, Folpe AL, Weiss SW. Epithelioid sarcoma-like hemangioendothelioma. Am J Surg Pathol 2003; 27: 48–57.
- 61Hornick JL, Fletcher CDM. Pseudomyogenic hemangioendothelioma: a distinctive, often multicentric tumor with indolent behavior. Am J Surg Pathol 2011; 35: 190–201.
- 62Nayler SJ, Rubin BP, Calonje E et al. Composite hemangioendothelioma: a complex, low-grade vascular lesion mimicking angiosarcoma. Am J Surg Pathol 2000; 24: 352–61.
- 63Reis-Filho JS, Paiva ME, Lopes JM. Congenital composite hemangioendothelioma: case report and reappraisal of the hemangioendothelioma spectrum. J Cutan Pathol 2002; 29: 226–31.
- 64Fukunaga M, Suzuki K, Saegusa N, Folpe AL. Composite hemangioendothelioma: report of 5 cases including one with associated Maffucci syndrome. Am J Surg Pathol 2007; 31: 1567–72.
- 65Sahin G, Palanduz A, Aydogan G et al. Classic Kaposi sarcoma in 3 unrelated Turkish children born to consanguineous kindreds. Pediatrics 2010; 125: 704–8.
- 66Abbas AAH, Jastaniah WA. Extensive gingival and respiratory tract Kaposi sarcoma in a child after allogenic hematopoietic stem cell transplantation. J Pediatr Hematol Oncol 2012; 34: 53–5.
- 67Hong Y-K, Foreman K, Shin JW et al. Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat Genet 2004; 36: 683–5.
- 68Dadras SS, Skrzypek A, Nguyen L et al. Prox-1 promotes invasion of kaposiform hemangioendotheliomas. J Invest Dermatol 2008; 128: 2798–806.
- 69Cossu S, Satta R, Cottoni F, Massarelli G. Lymphangioma-like variant of Kaposi's sarcoma: clinicopathologic study of seven cases with review of the literature. Am J Dermatopathol 1997; 19: 16–22.
- 70Grayson W, Pantanowitz L. Histological variants of cutaneous Kaposi sarcoma. Diagn Pathol 2008; 3: 31.
- 71Pak F, Pyakural P, Kokhaei P et al. HHV-8/KSHV during the development of Kaposi's sarcoma: evaluation by polymerase chain reaction and immunohistochemistry. J Cutan Pathol 2005; 32: 21–7.
- 72Pantanowitz L, Pinkus GS, Dezube BJ, Tahan SR. HHV8 is not limited to Kaposi's sarcoma. Mod Pathol 2005; 18: 1148.
- 73Rosado FGN, Itani DM, Coffin CM, Cates JM. Utility of immunohistochemical staining with FLI1, D2-40, CD31, and CD34 in the diagnosis of acquired immunodeficiency syndrome-related and non-acquired immunodeficiency syndrome-related Kaposi sarcoma. Arch Pathol Lab Med 2012; 136: 301–4.
- 74Molyneux E, Davidson A, Orem J et al. The management of children with Kaposi sarcoma in resource limited settings. Pediatr Blood Cancer 2013; 60: 538–42.
- 75Yuksekkaya HA, Arikan C, Yazici A et al. Successful treatment of a child having generalized Kaposi's sarcoma after living donor liver transplantation with conversion to sirolimus. Pediatr Transplant 2009; 13: 375–8.
- 76Deyrup AT, Miettinen M, North PE et al. Pediatric cutaneous angiosarcomas: a clinicopathologic study of 10 cases. Am J Surg Pathol 2011; 35: 70–5.
- 77Deyrup AT, McKenney JK, Tighiouart M et al. Sporadic cutaneous angiosarcomas: a proposal for risk stratification based on 69 cases. Am J Surg Pathol 2008; 32: 72–7.
- 78Morgan MB, Swann M, Somach S et al. Cutaneous angiosarcoma: a case series with prognostic correlation. J Am Acad Dermatol 2004; 50: 867–74.
- 79Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol 2002; 15: 434–40.
- 80Folpe AL, Veikkola T, Valtola R, Weiss SW. Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas. Mod Pathol 2000; 13: 180–5.
- 81Lasota J, Miettinen M. Absence of Kaposi's sarcoma-associated virus (human herpesvirus-8) sequences in angiosarcoma. Virchows Arch 1999; 434: 51–6.
- 82Baselga E, Cordisco MR, Garzon M et al. Rapidly involuting congenital haemangioma associated with transient thrombocytopenia and coagulopathy: a case series. Br J Dermatol 2008; 158: 1363–70.
